Labiotech.eu

News and Trends 1 Nov 2016

The Toilet has been Reinvented: Now it is Waterless!

About 1,400 children under 5 die of sanitation-related illnesses daily. The Cranfield Water Science Institute and the Gates Foundation may have a solution: a waterless toilet. Lack of access to clean water and proper sanitation is the main issue in third-world and developing countries, causing health issues and drinking water contamination. Over 2.4 billion people […]

November 1, 2016 - 5 minutesmins - By Joachim Eeckhout

News and Trends 31 Oct 2016

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops first-in-class antibody therapies for cancer. Its technology seems to be so promising that the Japanese Astellas Pharma has decided to acquire it in what will be the […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2016

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

Amcure’s candidate for highly metastatic epithelial cancers is about to start clinical trials. The compound can shut down three oncological pathways simultaneously through a single molecular target. Amcure is a spin-off from the Karlsruhe Institute of Technology in Germany, established in 2012. The company develops treatments for highly metastatic forms of cancer using peptide-based compounds targeting angiogenesis. It […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 31 Oct 2016

Meet the Jellyfish Medtech seeking to disrupt the Collagen Market

Jellyfish are a source of collagen: this is the idea behind the winner of Boost Cymru, a competition of the Life Sciences Hub Wales. We had a chat with Andrew Mearns-Spragg, CEO of Jellagen, about this promising startup. The jellyfish already has a place in Biotech’s hall of fame as the source of the gene for […]

October 31, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 29 Oct 2016

Aliens in the Cornfield: The Borg Are Taking over Nebraska

The assimilation of the human race has begun! A Star Trek nightmare is coming true, as biohackers recruit piercing artists to build human-based Borg. Similar to the Borg’s obsession with perfecting biological life through machinery, biohackers are driven to make human life easier with technological implants. The first trials have already begun, as some biohackers have […]

October 29, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 26 at 1.52.35 PM 1 e1477644606273

News and Trends 28 Oct 2016

Meet Spain’s Gold BIOMEDAList in Celiac Disease

This week we’re heading South back to my hometown, Sevilla! Even well into October, the skies are clear and the sun is shining while we drop by Biomedal, this week’s Biotech. City: Sevilla, Spain Founded: 2000 Employees: 31 Financial data: €2.5M in sales with an impressive 60% growth in the last year Mission: The company has three […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Oct 2016

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […]

October 28, 2016 - 2 minutesmins - By Dani Bancroft

Inside Labiotech 28 Oct 2016

Santé, Labiotech.eu is now 2 years old! (and what a journey so far)

Yes, it’s been already 2 years since Joachim and I moved to Berlin to work full-time on changing the media landscape of Biotech. And this second year has just been exceptional: we are now the leading digital media in Europe with 50k monthly visitors, a team of almost 10 people, solid investors, and over 50 customers. […]

October 28, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 27 Oct 2016

€36M Fundraising to Sequence the Genome of Ireland

Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of the Irish and use the info for the development of new drugs and diagnostics. Genomics Medicine Ireland (GMI) is committed to revolutionizing health care with whole-genome sequencing. The company just raised €36M ($40M) in Series A that will be used to […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

Boehringer enters the Biosimilar War against Blockbuster Humira

Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The Toilet has been Reinvented: Now it is Waterless!

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Meet the Jellyfish Medtech seeking to disrupt the Collagen Market

Aliens in the Cornfield: The Borg Are Taking over Nebraska

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Meet Spain’s Gold BIOMEDAList in Celiac Disease

UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type

Santé, Labiotech.eu is now 2 years old! (and what a journey so far)

€36M Fundraising to Sequence the Genome of Ireland

Boehringer enters the Biosimilar War against Blockbuster Humira

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!